
Sign up to save your podcasts
Or


Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.
By STAT4.5
320320 ratings
Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.

1,993 Listeners

753 Listeners

1,107 Listeners

821 Listeners

497 Listeners

127 Listeners

6,104 Listeners

62 Listeners

87 Listeners

35 Listeners

5,594 Listeners

55 Listeners

21 Listeners

399 Listeners

15 Listeners

12 Listeners